Avida Biomed Inc.

11:00 AM - 12:00 PM (PDT), Thursday, June 16, 2022
Avida Biomed, a biotech company founded by veteran entrepreneurs, focuses on technology-based innovation for molecular diagnostics with an emphasis on epigenetics analysis of cfDNA-based liquid biopsy. Avida’s newly launched Point-n-Seq™ kits enables genetics and epigenetics analysis with unprecedented sensitivity, dramatically shortened assay time, and full automation capacity, including the first kit for dual genomic and epigenomic analysis without sample splitting. Collaborating with clinical academic institutes, Point-n-Seq cancer early detection assays have demonstrated remarkable sensitivity and specificity. Ultimately, Avida strives to provide a fully automated cfDNA NGS platform to enable global access to the next level of clinical genomics.